Enrique Conterno

Type: Person
Name: Enrique Conterno
First reported Sep 23 2014 - Updated Sep 23 2014 - 1 reports

Lilly set to release Trulicity pen for type 2 diabetes

INDIANAPOLIS – Eli Lilly and Co. has been cleared to market Trulicity, a medication for type 2 diabetes.Lilly said Thursday Trulicity (dulaglutide) has been approved by the Food and Drug Administration an adjunct to diet and exercise to improve glycemic ... [Published Chain Drug Review - Sep 23 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

Eli Lilly: A Full Suite Of Offerings For Diabetic Patients

Summary Recently, Eli Lilly and Boehringer Ingelheim received a positive opinion from the European Medicines Agency for its insulin glargine, Abasria, for the treatment of diabetes. It's the first copycat of Sanofi's blockbuster Lantus, which raked ... [Published Seeking Alpha - Sep 22 2014]
First reported Sep 19 2014 - Updated Sep 20 2014 - 1 reports

Eli Lilly's Trulicity approved by FDA

SILVER SPRING, Md. and INDIANAPOLIS —  The Food and Drug Administration on Thursday approved Trulicity (dulaglutide), a once-a-week injection to improve blood-sugar levels in adults with Type 2 diabetes."Type 2 diabetes is a serious chronic condition ... [Published Drug Store News - Sep 19 2014]
First reported Sep 18 2014 - Updated Sep 19 2014 - 3 reports

Lilly Says FDA Approves Type 2 Diabetes Drug Trulicity

Drugmaker Eli Lilly and Co. (LLY: Quote) announced Thursday that the U.S. Food and Drug Administration has approved Trulicity (dulaglutide) as the latest treatment option for adults with type 2 diabetes. Trulicity is not insulin, but acts like glucagon-like ... [Published RTTNews.com - Sep 19 2014]
First reported Sep 15 2014 - Updated Sep 16 2014 - 1 reports

Lilly and Boehringer win regulatory approval for insulin glargine product in EU

Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. have received marketing authorization from the European Commission, or EC, for insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged two years ... [Published Individual.com - Sep 15 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Eli Lilly announces encouraging results from Phase III type 1 diabetes trials

Eli Lilly and Company has announced that its basal insulin peglispro, or BIL, demonstrated a statistically significant lower hemoglobin A1c, or HbA1c, compared with insulin glargine at 26 weeks and 52 weeks, respectively, in the IMAGINE-1 and IMAGINE-3 ... [Published Individual.com - Sep 12 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Lilly and Boehringer Ingelheim receive EU approval for biosimilar insulin

:03 in Pharmaceutical Company Product News Lilly and Boehringer Ingelheim have been granted European regulatory approval for their groundbreaking new insulin glargine product for diabetes patients. Indicated to treat diabetes in adults, adolescents and ... [Published Zenopa - Sep 12 2014]
First reported Sep 10 2014 - Updated Sep 11 2014 - 1 reports

Lilly and Boehringer snag EU nod for Lantus knockoff, but stateside hopes stay on ice

Lilly Diabetes President Enrique ConternoEli Lilly ($LLY) and Boehringer Ingelheim won European clearance for their biosimilar of Lantus, Sanofi's ($SNY) top-selling insulin product, but the treatment's full potential remains hamstrung by a U.S. patent ... [Published FierceBiotech - Sep 10 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

Lilly reports positive data from diabetes drug trials

:21 in Pharmaceutical Company Product News Lilly has announced positive data from head-to-head trials that compared its new basal insulin peglispro (BIL) against an established diabetes therapy. Results from the IMAGINE-1 and IMAGINE-3 phase III clinical ... [Published Zenopa - Sep 10 2014]
First reported Sep 04 2014 - Updated Sep 05 2014 - 1 reports

Eli Lilly says peglispro bests Sanofi's Lantus in type 1 diabetes studies

Eli Lilly announced Thursday that its experimental basal insulin peglispro demonstrated significantly lower HbA1c compared with Sanofi's Lantus (insulin glargine) at 26 weeks and 52 weeks in two late-stage trials in patients with type 1 diabetes. The ... [Published FirstWord Pharma - Sep 04 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 1 reports

US FDA approves Jardiance tablets for adults with type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company announced the US Food and Drug Administration (FDA) approved Jardiance (empagliflozin) tablets as an adjunct to diet and exercise to improve glycemic control, or blood glucose ... [Published PharmaBiz - Aug 05 2014]
First reported Jun 30 2014 - Updated Jun 30 2014 - 1 reports

CHMP recommends Lilly/Boehringer's new insulin glargine product for approval in EU to treat type 1 and type 2 diabete

The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes. The new insulin glargine ... [Published PharmaBiz - Jun 30 2014]

More Content

All (25) | News (25) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Lilly set to release Trulicity pen for type 2 d... [Published Chain Drug Review - Sep 23 2014]
Eli Lilly: A Full Suite Of Offerings For Diabet... [Published Seeking Alpha - Sep 22 2014]
Eli Lilly's Trulicity receives US FDA approval ... [Published PharmaBiz - Sep 20 2014]
FDA approves new Lilly type 2 diabetes therapeutic [Published Drug Discovery News - Sep 19 2014]
Eli Lilly and Company Gets Thumbs Up From FDA F... [Published BioSpace - Sep 19 2014]
Eli Lilly's Trulicity approved by FDA [Published Drug Store News - Sep 19 2014]
Lilly Says FDA Approves Type 2 Diabetes Drug Tr... [Published RTTNews.com - Sep 19 2014]
FDA approves dulaglutide to treat type 2 diabetes [Published Orthopedics Today - Sep 18 2014]
FDA Approves Trulicity(TM) (dulaglutide), Lilly... [Published Scottrade - Sep 18 2014]
Lilly and Boehringer win regulatory approval fo... [Published Individual.com - Sep 15 2014]
Eli Lilly announces encouraging results from Ph... [Published Individual.com - Sep 12 2014]
Lilly and Boehringer Ingelheim receive EU appro... [Published Zenopa - Sep 12 2014]
Lilly and Boehringer diabetes biosimilar sees E... [Published Pharmafocus - Sep 11 2014]
EU approval for Boehringer and Lilly’s insulin ... [Published Pharma Letter - Sep 10 2014]
EC Grants Marketing Authorization for Lilly-BI ... [Published Drug Discovery and Development - Sep 10 2014]
Lilly and Boehringer snag EU nod for Lantus kno... [Published FierceBiotech - Sep 10 2014]
Lilly reports positive data from diabetes drug ... [Published Zenopa - Sep 10 2014]
Lilly's peglispro shows HbA1c superiority again... [Published Pharma Letter - Sep 04 2014]
Lilly claims another head-to-head victory over ... [Published FierceBiotech - Sep 04 2014]
Eli Lilly says peglispro bests Sanofi's Lantus ... [Published FirstWord Pharma - Sep 04 2014]
Lilly's Basal Insulin Peglispro Demonstrated Hb... [Published TickerTech.com - Sep 04 2014]
US FDA approves Jardiance tablets for adults wi... [Published PharmaBiz - Aug 05 2014]
CHMP recommends Lilly/Boehringer's new insulin ... [Published PharmaBiz - Jun 30 2014]
EU grants marketing approval for Jardiance tabs... [Published PharmaBiz - May 24 2014]
Lilly's phase III trial for once-weekly dulaglu... [Published PharmaBiz - Feb 27 2014]
1
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.